Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
상품코드:1880371
리서치사:MarketsandMarkets
발행일:2025년 10월
페이지 정보:영문 377 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 분자 세포 유전학 시장 규모는 2025년 10억 2,000만 달러에서 2030년에는 14억 3,000만 달러에 이를 것으로 예측되어 예측 기간에 CAGR` 7.1%의 성장이 전망됩니다.
이 시장의 성장은 주로 노인을 대상으로 한 암과 유전성 질환의 유병률 증가에 의해 주도되고 있습니다. 또한, 정확한 진단과 질병 관리를 위한 분자 세포유전학적 검사의 활용 확대도 중요한 역할을 하고 있습니다.
조사 범위
조사 대상 기간
2024-2030년
기준 연도
2024년
예측 기간
2025-2030년
단위
10억 달러
부문
제품 및 서비스, 기법, 용도, 최종사용자
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카
또한, 표적 치료의 등장과 개인 맞춤형 의료로의 통합은 시장 성장을 더욱 촉진하고 있습니다. 그러나 첨단 분자세포유전학 기법에 따른 높은 비용과 숙련된 전문가의 필요성은 시장 확대에 큰 장벽으로 작용하고 있습니다.
"테스트 키트 부문은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예측됩니다. "
분자 세포 유전학 시장에서 테스트 키트 부문은 사용 편의성, 재현성, 신속하고 정확한 결과를 제공하는 능력으로 인해 가장 높은 CAGR로 성장하고 있습니다. CGH 어레이와 FISH 프로브 패널을 포함한 이들 키트는 임상 실험실 및 연구소에서 염색체 이상 및 유전자 변이를 표준화된 방식으로 검출할 수 있도록 합니다. 검증된 분석법과 통합 분석 툴을 활용하여, 검사 키트는 종양학, 산전 검사, 유전 질환 진단을 지원하는 신뢰할 수 있는 고처리량 솔루션을 제공합니다. 검사 키트는 편리성, 정확성, 확장성으로 인해 효율적인 세포유전학 검사에 필수적이며, 시장에서의 강력한 채택을 촉진하고 있습니다.
"암 분야가 시장에서 가장 큰 점유율을 차지하고 있습니다. "
분자세포유전학 시장에서 가장 큰 비중을 차지하는 분야는 암 응용 분야입니다. 이러한 성장은 주로 전 세계적으로 암 발병률 증가, 특히 악성종양에 취약한 노년층의 암 발병률 증가에 기인합니다. 유전적 변화와 염색체 이상은 종양 발생의 주요 원인으로, 종양학에서 분자 세포유전학적 검사에 대한 수요가 증가하고 있습니다. 형광 in situ hybridization(FISH), 비교유전체하이브리데이션(CGH) 등의 기법을 통해 이러한 이상을 정확하게 검출할 수 있어 정확한 진단, 종양 유형 분류, 질병 진행 모니터링이 용이해집니다. 또한, 암 연구에 대한 투자 증가, 의료 인프라 개선, 조기 발견 및 유전자 프로파일링의 이점에 대한 인식이 높아짐에 따라 전 세계 임상 및 연구 환경 전반에 걸쳐 이 부문의 강력한 성장에 기여하고 있습니다.
"미국은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예측됩니다. "
여러 요인으로 인해 미국이 분자세포유전학 시장에서 가장 높은 성장률을 보이고 있습니다. 주요 세포유전학 기업의 존재, 선진화된 연구 인프라 및 대규모 환자 기반은 이 나라 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다. 또한, 종양학, 산전 검사, 유전성 질환 진단에서 분자 세포 유전학 검사의 채택이 증가함에 따라 수요를 촉진하고 있습니다. 의료 규제 지원 체계, 유전체 연구 자금 지원 증가, 정밀의료에 대한 관심 증가도 미국 분자세포유전학 시장 확대에 기여하고 있습니다.
또한, 염색체 이상을 정확하게 검출하기 위한 FISH, CGH와 같은 분자세포유전학 기법의 광범위한 채택은 분자세포유전학의 성장을 가속하고 있습니다. 정부와 민간의 생물 의학 연구 및 종양학에 대한 막대한 자금 지원은 혁신을 가속화하고 최첨단 검사 플랫폼의 개발을 촉진하고 있습니다. 이 지역의 엄격한 규제 프레임워크는 제품의 품질과 신뢰성을 보장하고, 분자 세포 유전학 솔루션에 대한 신뢰를 더욱 강화하며, 북미의 세계 우위를 확고히 하고 있습니다.
세계의 분자세포유전학 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.
The molecular cytogenetics market is expected to reach USD 1.43 billion in 2030 from USD 1.02 billion in 2025, at a CAGR of 7.1% during the forecast period. The market is driven by a rising prevalence of cancer and genetic disorders, mainly among older adults. The growing application of molecular cytogenetic tests for accurate diagnosis and disease management also plays a crucial role.
Scope of the Report
Years Considered for the Study
2024-2030
Base Year
2024
Forecast Period
2025-2030
Units Considered
Value (USD billion)
Segments
Product & Service, Technique, Applications, End User
Regions covered
North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
Furthermore, the emergence of targeted therapies and their integration into personalized medicine are further driving market growth. Nonetheless, the high expenses associated with advanced molecular cytogenetic techniques and the requirement for skilled professionals continue to be major barriers to market expansion.
"Testing kits segment is expected to grow at the highest CAGR during the forecast period"
The testing kits segment is growing at the highest CAGR in the molecular cytogenetics market due to its ease of use, reproducibility, and ability to deliver rapid, accurate results. These kits, including CGH arrays and FISH probe panels, enable standardized detection of chromosomal abnormalities and genetic variations across clinical and research laboratories. By leveraging pre-validated assays and integrated analysis tools, testing kits offer reliable, high-throughput solutions that support oncology, prenatal testing, and genetic disorder diagnostics. Their convenience, accuracy, and scalability make them essential for efficient cytogenetic testing, driving their strong adoption in the market.
"Cancer application segment holds the largest share of the market"
The cancer applications segment accounts for the largest share of the molecular cytogenetics market. This growth is primarily driven by the rising incidence of cancer worldwide, particularly among the aging population, which is more susceptible to malignancies. Genetic changes and chromosomal abnormalities are major contributors to tumor development, increasing the demand for molecular cytogenetic testing in oncology. Techniques such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) enable the precise detection of these abnormalities, facilitating accurate diagnosis, classification of tumor types, and monitoring of disease progression. Furthermore, increasing investments in cancer research, improvements in healthcare infrastructure, and growing awareness of the benefits of early detection and genetic profiling are contributing to the robust growth of this segment across clinical and research settings globally.
"US is expected to grow at the highest CAGR during the forecast period"
The US is experiencing the highest growth rate in the molecular cytogenetics market due to several factors. The presence of leading cytogenetics companies, advanced research infrastructure, and a large patient base are major drivers of market growth in the country. Additionally, rising adoption of molecular cytogenetic testing in oncology, prenatal screening, and genetic disorder diagnostics is fueling demand. Supportive healthcare regulations, increased funding for genomic research, and the growing focus on precision medicine further contribute to the expansion of the molecular cytogenetics market in the US.
Additionally, the widespread adoption of molecular cytogenetic techniques, such as FISH and CGH, for the accurate detection of chromosomal abnormalities has further supported the growth of molecular cytogenetics. Extensive government and private funding for biomedical research and oncology accelerates innovation and the deployment of cutting-edge testing platforms. The region's stringent regulatory framework ensures product quality and reliability, further strengthening trust in molecular cytogenetic solutions and solidifying North America's dominant position globally.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Tier 1 - 25%, Tier 2 - 35%, and Tier 3 - 40%
By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, the Middle East - 10%, and Africa - 5%
F. Hoffmann-La Roche Ltd. (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Revvity (US), PacBio (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), GeneDx, LLC (US), Insight Molecular Diagnostics Inc. (US), BioView (Israel), Oxford Gene Technology IP Limited (UK), Applied Spectral Imaging, Inc. (US), CytoTest Inc. (US), KROMATID (US), Genial Genetic Solutions Ltd. (UK), Cytognomix Inc. (Canada), MetaSystems (Germany), SciGene Corporation (US), Biomodal (UK), Biocare Medical, LLC (US), BioDot (US), and OncoDNA (Belgium) are some of the key companies offering molecular cytogenetics products.
Research Coverage
This research report categorizes the molecular cytogenetics market by product & service (kits & reagents [testing kits, probes, fluorescent affinity reagents, other kits & reagents], instruments, consumables, software & services), technique (comparative genomic hybridization [array-based comparative genomic hybridization, standard comparative genomic hybridization], fluorescence in-situ hybridization, chromogenic in-situ hybridization, other techniques), application (cancer, genetic disorders, personalized medicine and other applications), end user (clinical & research laboratories, academic & research institutes, pharmaceutical & biotechnology companies, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).
The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the molecular cytogenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the molecular cytogenetics market. This report also includes a competitive analysis of emerging startups in the molecular cytogenetics industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, and increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments and unfavourable reimbursement scenario), opportunities (untapped emerging markets), and challenges (transition from FISH to array-based techniques) influencing the market growth
Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the molecular cytogenetics market
Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including F. Hoffman-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), among others offering products and services for molecular cytogenetics market. Other companies include Applied Spectral Imaging Inc. (US), Biomodal (UK), Biocare Medical, LLC (US), OncoDNA (Belgium), among others, for the molecular cytogenetics market
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION, 2024
